Androst Biotech

Androst Biotech is a clinical-stage biotechnology company focused on the development of 5-androstenediol (5-AED) as a medical countermeasure for radiation injury and infectious diseases. The company's lead candidate, 5-AED, is a naturally occurring adrenal steroid that has demonstrated the ability to stimulate the production of white blood cells and platelets, which is critical for treating Acute Radiation Syndrome (ARS). Originally researched by the Armed Forces Radiobiology Research Institute, the therapy is being advanced by Androst Biotech to address gaps in national defense and public health preparedness. In addition to its radioprotective applications, the company is investigating the immunomodulatory potential of 5-AED in mitigating the severity of viral infections, including influenza and COVID-19. Androst Biotech operates primarily through strategic collaborations and government-funded research initiatives to bring its steroid-based therapies to market.